Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy

In recent years, cancer immunotherapy has undergone a transformative shift toward personalized and targeted therapeutic strategies. Bacteria‐derived outer membrane vesicles (OMVs) have emerged as a promising and adaptable platform for cancer immunotherapy due to their unique properties, including na...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced Science 2024-09, Vol.11 (33), p.e2400049-n/a
Hauptverfasser: Luo, Ziheng, Cheng, Xiang, Feng, Bin, Fan, Duoyang, Liu, Xiaohui, Xie, Ruyan, Luo, Ting, Wegner, Seraphine V., Ma, Dayou, Chen, Fei, Zeng, Wenbin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In recent years, cancer immunotherapy has undergone a transformative shift toward personalized and targeted therapeutic strategies. Bacteria‐derived outer membrane vesicles (OMVs) have emerged as a promising and adaptable platform for cancer immunotherapy due to their unique properties, including natural immunogenicity and the ability to be engineered for specific therapeutic purposes. In this review, a comprehensive overview is provided of state‐of‐the‐art techniques and methodologies employed in the engineering of versatile OMVs for cancer immunotherapy. Beginning by exploring the biogenesis and composition of OMVs, unveiling their intrinsic immunogenic properties for therapeutic appeal. Subsequently, innovative approaches employed to engineer OMVs are delved into, ranging from the genetic engineering of parent bacteria to the incorporation of functional molecules. The importance of rational design strategies is highlighted to enhance the immunogenicity and specificity of OMVs, allowing tailoring for diverse cancer types. Furthermore, insights into clinical studies and potential challenges utilizing OMVs as cancer vaccines or adjuvants are also provided, offering a comprehensive assessment of the current landscape and future prospects. Overall, this review provides valuable insights for researchers involved in the rapidly evolving field of cancer immunotherapy, offering a roadmap for harnessing the full potential of OMVs as a versatile and adaptable platform for cancer treatment. Outer membrane vesicles (OMVs) derived from bacteria present an adaptable platform for cancer immunotherapy. The unique properties of OMVs underscore their potential, including natural immunogenicity and accessibility to engineering for specific therapeutic goals. They exhibit excellent biocompatibility, drug‐loading capacity, and modifiability, which enable modifications through genetic engineering, surface functionalization, the construction of hybrid membrane vesicles and drug delivery platforms.
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202400049